Veterinary (Pet) Antibody-Drug Conjugate (ADC) Development Service

Are you facing challenges in developing novel, effective, and safe treatments for companion animals? The complexity of creating targeted biologics, from antibody engineering to cytotoxic payload conjugation, can slow down your research and development pipeline. Creative Biolabs' veterinary antibody-drug conjugate (ADC) development service helps you accelerate the creation of next-generation pet therapeutics. Through our integrated platform, combining expert veterinary antibody engineering with advanced bioconjugation strategies, we deliver potent and highly specific ADCs tailored for canine and feline targets, paving the way for safer and more effective treatments.

Introduction

Antibody-Drug Conjugates. (Creative Biolabs Original)

Creative Biolabs transforms your initial concept into a well-characterized, potent, and purification-ready veterinary ADC candidate poised for advanced preclinical evaluation. Our service is a comprehensive, end-to-end solution designed to navigate the complexities of ADC development, from initial antibody optimization to final bioanalytical characterization. We partner with you to design and construct an ADC with the ideal therapeutic window, balancing high efficacy against cells with minimal toxicity. Our team delivers a molecule built on a foundation of deep expertise in both veterinary immunology and bioconjugate chemistry, providing a clear path forward for your therapeutic program.

Request a Consultation

Workflow

Antibody Isotype Switching Workflow. (Creative Biolabs Original) Fig 1. Antibody Isotype Switching Service Workflow. (Creative Biolabs Original)

Project Consultation & Feasibility Assessment	We begin by understanding your target species, disease indication, and therapeutic goals. Our scientific team evaluates the suitability of ADC technology for your application and outlines a tailored development strategy, including antibody selection, payload choice, and linker chemistry.
Antibody Selection & Engineering	We identify or generate high-affinity monoclonal antibodies specific to your veterinary target. Antibodies can be engineered for optimal conjugation sites, species compatibility, and desired isotypes, ensuring effective targeting and reduced immunogenicity in companion animals.
Linker-Payload Design & Conjugation Strategy	We design a customized linker-payload system using either cleavable or non-cleavable linkers, matched with cytotoxic agents or functional payloads appropriate for veterinary safety and efficacy. Our conjugation chemistries (e.g., lysine-, cysteine-, or site-specific conjugation) are optimized to maintain antibody functionality and control drug-to-antibody ratio (DAR).
ADC Synthesis & Purification	Your antibody is conjugated with the selected payload using validated protocols. The ADC product is purified and characterized through SEC, HIC, and mass spectrometry to ensure homogeneity, stability, and precise DAR profiling.
Antibody In Vitro Evaluation	We assess the biological activity of the ADC using species-relevant in vitro assays. This includes antigen binding validation, target cell internalization, and cytotoxicity testing against relevant veterinary cancer cell lines or primary cells.
Data Reporting & Optional Downstream Support	A comprehensive data report is delivered, including ADC structure, DAR analysis, in vitro performance, and quality metrics. We also offer downstream services such as pharmacokinetic studies, safety profiling, and efficacy testing in animal models to support your veterinary ADC program through preclinical development.

Why Choose Us?

Unparalleled Veterinary Focus
Unlike generalist CROs, our services are built from the ground up for companion animals. Our expertise in canine and feline immunology, including proprietary algorithms for antibody caninization and felinization, ensures the development of biologics with lower immunogenicity risk and higher clinical translation potential.
Integrated One-Stop Platform
We manage every step of the process internally, from gene synthesis and antibody expression to linker-payload chemistry, conjugation, and in vitro evaluation. This seamless integration eliminates the logistical hurdles and communication gaps of using multiple vendors, saving you valuable time and resources.
Advanced Customization & Technology
We don't believe in a one-size-fits-all approach. We offer a diverse library of linkers and payloads and employ both classic stochastic and modern site-specific conjugation technologies. This allows us to precisely engineer the Drug-to-Antibody Ratio (DAR) and create a highly optimized, homogenous ADC tailored to your specific target and therapeutic goals.

FAQs

1. What is the Drug-to-Antibody Ratio (DAR), and why is it important?

The DAR is the average number of drug molecules attached to each antibody. It is a critical quality attribute that profoundly impacts the ADC's efficacy and safety. A low DAR may not be potent enough, while a high DAR can lead to instability and off-target toxicity. We use advanced conjugation and analytical techniques to precisely control and measure the DAR, aiming for the optimal therapeutic window.

2. How do you help ensure the safety of the ADC for pets?

We achieve this through several mechanisms: 1) Engineering a species-specific antibody to reduce immunogenicity. 2) Selecting highly stable linkers that only release the payload inside the target cancer cell. 3) Performing rigorous in vitro cytotoxicity testing on non-target cells to confirm specificity before delivering the final product to you.

Related Services

To fully support your veterinary ADC development pipeline, Creative Biolabs offers a suite of complementary specialized services.

Antibody Caninization Service

Reduce immunogenicity in dogs by grafting your lead antibody's CDRs onto canine frameworks for enhanced safety and therapeutic efficacy.

Antibody Felinization Service

Optimize antibody compatibility in feline patients through precise CDR grafting onto feline germline sequences to lower ADA risk and improve tolerance.

Antibody Characterization

Validate the identity, stability, and functionality of your veterinary antibody with detailed structural, biophysical, and binding analyses.

Pet Therapeutic Antibody Evaluation

Assess your candidate's biological activity using species-relevant assays and animal models to generate decision-driving efficacy and safety data.

Partner with Creative Biolabs

Creative Biolabs is your dedicated partner in advancing veterinary medicine. Our specialized ADC development service provides the expertise, technology, and integrated support necessary to bring your most promising therapeutic concepts to life. We are committed to helping you create safer, more effective treatments for the companion animals that need them.

Ready to discuss your project? Our team of experts is available to answer your questions and provide a detailed proposal tailored to your specific needs. Contact our team to discover how we can help with your ADC development project.

Contact Our Team

Services